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hospitalization, or were discharged free of 
HFrEF despite reduced LVEF.
Methods The rationale and methodology of 
the PL ‑ACS registry were described elsewhere.5 
As we presented the subanalysis of the already 
approved registry study, no ethics committee 
approval was required. The registry included 
755 947 patients with AMI, among whom EF 
was reported in 42 504, and 8287 (19.5%) of 
them presented EF below 40%. Finally, we in‑
cluded 7647 consecutive patients hospitalized 
between January 2018 and December 2019 and 
discharged alive with LVEF below 40%.
Statistical analysis Categorical variables were 
presented as percentages. Normally distrib‑
uted continuous variables were expressed as 
mean (SD), and those with distribution oth‑
er than normal—as median (interquartile 
range [IQR]).
Introduction Cardiovascular diseases are 
the main cause of death in developed coun‑
tries.1 Coronary artery disease (CAD) accounts 
for around two ‑third of cases of left ventricu‑
lar systolic dysfunction (LVSD) and heart fail‑
ure with reduced ejection fraction (HFrEF).2,3
Acute myocardial infarction (AMI) is the lead‑
ing cause of LVSD increasing the risk of HFrEF 
and worse clinical outcomes.4 Therefore, opti‑
mal hospital treatment of AMI and proper dis‑
charge therapy is a key issue in patients with 
LVSD or HFrEF.
In this short communication, we analyzed 
the population of patients with AMI using 
the Polish Registry of Acute Coronary Syn‑
dromes (PL ‑ACS). Our objective was to assess 
the clinical and treatment characteristics of 
patients with left ventricular ejection frac‑
tion (LVEF) below 40% at discharge regardless 
of whether they had HFrEF before AMI, devel‑
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respectively. Furthermore, 21% of the study pa‑
tients had a history of paroxysmal or persistent 
atrial fibrillation.
The most frequent comorbidities were hyper‑
tension (72.6%), hyperlipidemia (47.6%), diabe‑
tes (35.1%), chronic kidney disease (14%), pe‑
ripheral artery disease (10%), and a history of 
stroke (8.5%).
Resuscitated cardiac arrest was reported 
in 4% of the study patients before admission 
and in 1.4% during hospitalization. A total of 
69.6% of the patients presented with Killip class 
I, whereas 20.1%, 7%, and 3.3% with Killip class 
II, III, or IV, respectively. On admission or dur‑
ing hospitalization, 2.3% and 2.7% of the pa‑
tients developed cardiac shock or were treated 
Results and discussion The mean (SD) age 
of the study patients was 69.4 (10.8) years, and 
71.2% of them were men. On admission, 60.9% of 
the patients presented with non–ST ‑segment ele‑
vation myocardial infarction, and 39.1% with ST‑
‑segment elevation myocardial infarction. A his‑
tory of AMI was reported in 35.1% of individ‑
uals. Among the study patients, 84.3% already 
underwent percutaneous coronary interven‑
tion, whereas 2.1% had coronary artery bypass 
graft. Before admission, a history of heart fail‑
ure was present in 24.9% of the patients, among 
whom 3.5%, 1.3%, and 2.6% were previously 
implanted with an implantable cardioverter‑
‑defibrillator (ICD), a cardiac resynchronization 
therapy defibrillator (CRT ‑D), or a pacemaker, 
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acetylsalicylic acid administration: 95.9% in 
the PL ‑ACS registry versus 98.2% in the Pro ‑ACS 
registry, and P2Y12 inhibitor use was lower in 
the PL ‑ACS registry: 86% versus 98.6%, which 
was probably related to the difference in the fre‑
quency of surgical treatment: 8.7% in the PL‑
‑ACS registry versus 0% in the Pro ‑ACS regis‑
try. The use of statins was lower in the PL ‑ACS 
registry: 80% versus 93.4%. In the PL ‑ACS regis‑
try compared with the Pro ‑ACS registry, the fre‑
quency of β ‑blocker and ACEI / angiotensin II re‑
ceptor blocker (ARB) / angiotensin receptor ne‑
prilysin inhibitor (ARNI) therapy in patients 
with LVEF less than 40% was 77.7% versus 87.5% 
and 85% versus 79.7%. The difference in the use 
of ACEIs / ARBs / ARNIs might be related to in‑
clusion of patients with a history of HFrEF in 
the PL ‑ACS registry, although the prevalence of 
acute HF complicating AMI was similar in both 
registries. In the QUALIFY survey focusing on 
HFrEF of various etiologies, β ‑blockers (96.7%) 
and any renin–angiotensin–aldosterone system 
blockers (91.9%) were used more often compared 
with data from the PL ‑ACS registry.12
Diuretics are recommended to improve symp‑
toms and exercise capacity in HFrEF.10 Compared 
with the QUALIFY survey, diuretics were less of‑
ten used in our study cohort: 67% versus 86%. 
However, a higher proportion of the QUALIFY 
survey population was symptomatic, and near‑
ly 90% of those patients presented with NYHA 
class II or III.12
Mineralocorticoid receptor antagonists 
(MRAs) should be used in symptomatic HFrEF 
despite treatment with ACEIs / ARBs / ARNIs and 
β ‑blockers.5 In the PL ‑ACS registry, the Pro ‑ACS 
registry, and the QUALIFY survey, the frequency 
of MRA administration was 33.2%, 35.7%, and 
73.2%, respectively.12 The higher rate of MRA use 
in the QUALIFY survey may be explained by in‑
clusion of a more symptomatic population with 
HFrEF (NYHA class: I, 13%; II, 46%; III, 36%; 
and IV, 5%). The main inclusion criterion for 
the PL ‑ACS and Pro ‑ACS registries was LVEF 
less than 40%, independently of symptoms.9
The same difference in patient characteris‑
tics may explain the variability of ivabradine 
use. Ivabradine is recommended in symptomat‑
ic patients with LVEF less than or equal to 35%, 
sinus rhythm, and a resting heart rate higher 
than or equal to 70 bpm despite treatment with 
evidence ‑based drugs.10 According to the PL ‑ACS 
registry and the QUALIFY survey, ivabradine 
was prescribed in 3.5% and 13.9% of patients, 
respectively, whereas the proportion of patients 
on this drug was not reported in the Pro ‑ACS 
registry.11,12
Lack of reimbursement for ARNIs in Po‑
land accounts for the prescription rate of these 
drugs reaching only 1.4% in the PL ‑ACS reg‑
istry. Following the European Society of Car‑
diology guidelines, ARNIs are recommended 
for pulmonary edema, respectively. Left ventric‑
ular augmentation with an intra ‑aortic balloon 
pump was performed in 0.7% of the patients. 
The degree of left ventricular dysfunction (Killip 
class) as part of the ANIN risk score seemed to 
be a crucial predictor of long ‑term all‑cause and 
cardiovascular mortality.6
On admission, sinus rhythm was present in 
84.5% of the patients (median [IQR] heart rate, 
80  [70–98] bpm).
All patients underwent coronary angiography 
(the radial approach was used in 79.9% of them). 
Multivessel disease was diagnosed in a total of 
49.4% of the patients and in 81.3% treated with 
percutaneous coronary intervention, whereas 
4.5% and 4.2% were eligible for urgent or elec‑
tive coronary artery bypass graft, respective‑
ly. 12.4% of the patients who were ineligible for 
coronary intervention received pharmacolog‑
ic treatment.
During hospitalization, a peacemaker, an ICD, 
or a CRT ‑D were implanted in 0.5%, 0.5%, and 
0.07% of the patients, respectively.
At discharge, 35.6% of the study patients pre‑
sented with New York Heart Association (NYHA) 
functional class I, whereas 48.9%, 13.4%, and 
2.1% with NYHA class II, III, or IV respective‑
ly. The median (IQR) LVEF was 31% (27%–35%), 
mean (SD) left ventricular diastolic dimension 
55 (10) mm, and severe or mild mitral regurgita‑
tion was observed in 2.6% and 11.2% of the pa‑
tients, respectively.
According to the recent European Society of 
Cardiology guidelines, patients after AMI with 
reduced LVEF and HFrEF should receive phar‑
macotherapy related to AMI, drugs that can al‑
ter a history of LVSD, and medication reliev‑
ing symptoms, indicated for secondary preven‑
tion and treatment of comorbidities.5 Detailed 
data on pharmacotherapy applied at discharge 
is shown in TABLE 1.
Registries provide limited data on medication 
in patients surviving AMI with LVSD or HFrEF. 
Most of them do not stratify for LVEF,7 limit in‑
clusion to already established ischemic HFrEF 
excluding asymptomatic LVSD,8 or include pa‑
tients with mixed etiology of HFrEF.9 Therefore, 
differences between patient characteristics make 
comparisons difficult.
The  use of β  ‑blockers and angiotensin‑
‑converting enzyme inhibitors (ACEIs) is recom‑
mended in LVSD or HFrEF.10 The Portuguese Reg‑
istry of Acute Coronary Syndromes (Pro ‑ACS) 
recruited patients with ischemic HFrEF,11 but 
excluded those with a history of HFrEF before 
AMI, while such patients in our study repre‑
sented 24.9% of the participants. The clinical 
characteristics of both populations were sim‑
ilar, except diabetes not reported in the Pro‑
‑ACS registry. The comparison of the PL ‑ACS 
and Pro ‑ACS registry data showed that anti‑
platelet treatment proved to be comparable with 
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as replacement drugs for ACEIs in HFrEF still 
symptomatic despite optimal treatment with 
an ACEI, a β ‑blocker, and an MRA.10
Implantable cardioverter ‑defibrillator im‑
plantation is recommended in HFrEF (NYHA 
class II–III) with LVEF less than or equal to 35% 
after 3 months of optimal medical therapy. In 
the PL ‑ACS registry, 25.5% of the patients had 
HFrEF before ACS, and further 29.8% devel‑
oped HFrEF during hospitalization (Killip class 
II–IV). Thus, about half of the patients were free 
of HFrEF and 29.8% did not complete the re‑
quired medical treatment. The rate of ICD and 
CRT implantations in the PL ‑ACS registry was 
very low.10
Conclusions Despite clear recommendations 
for pharmacologic treatment and device therapy, 
a still too small proportion of patients surviving 
AMI with LVEF below 40% and HFrEF or only 
asymptomatic LVSD do receive such therapy.
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